CLOs on the Move

Alnylam

www.alnylam.com

 
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.alnylam.com
  • 300 Third Street 3rd Floor
    Cambridge, MA USA 02142
  • Phone: 617.551.8200

Executives

Name Title Contact Details
Melissa McLaughlin
Chief Human Resources Officer Profile
Piyush Sharma
Chief Ethics and Compliance Officer Profile
Agnieszka Gallagher
Senior Vice President and Chief Compliance Officer Profile
Agnieszka Gallagher
Senior Vice President and Chief Ethics and Compliance Officer Profile
Sara Nochur
Chief Regulatory Officer Profile

Similar Companies

Natural Health Trends

Natural Health Trends Corp. is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Regency Hospital Company

Regency Hospital Company, LLC is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Regency Hospital Company, LLC is based in Alpharetta, GA. You can find more information on Regency Hospital Company, LLC at www.regencyhospital.com

Fibrocell Science

Making an impact on rare and serious skin and connective tissue diseases Fibrocell Science is at the forefront of the exciting and promising field of personalized biologics. By extracting cells from skin to create localized therapies that are compatible with the unique biology of each patient, personalized biologics bring a transformational approach to drug development. It is Fibrocell’s scientific leadership and legacy in cultivating and harnessing autologous fibroblast cells that fuels its personalized biologics approach. Fibrocell’s proprietary technology uses a person’s own fibroblast cells – with or without genetic modification – to target localized treatment of rare and serious skin and connective tissue diseases.

Imagin Medical

Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin`s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors.

Healthcare Integrated Technologies

Healthcare Integrated Technologies, Inc. is focused on developing effective, non-intrusive, resident monitoring technologies for senior living communities. Healthcare Integrated Technologies is headquartered in Knoxville, Tennessee.